Annals of Thoracic Surgery最新文献

Background: The cause of increased risk for reoperation after transcatheter aortic valve replacement (TAVR) vs prior surgical aortic valve replacement (SAVR) is poorly understood. This study evaluated the impact of concomitant mitral and tricuspid valve disease on associated risk of TAVR explantation.

Methods: Patients undergoing aortic valve replacement after prior SAVR or TAVR were extracted from The Society of Thoracic Surgeons Adult Cardiac Surgery Database (2011-2021). Patients were stratified by TAVR explantation status and presence of severe concomitant valve disease for analyses. Risk adjustment was performed by multivariable logistic regression. Interaction terms were used to evaluate differential risk of concomitant valve disease for TAVR explantation vs redo-SAVR.

Results: Of 24,097 redo aortic valve replacement patients, 877 (3.6%) underwent TAVR explantation. TAVR explantation patients had higher rates of concomitant severe valve disease (17% vs 14%; P < .001). Patients with severe concomitant valve disease had worse operative mortality after TAVR explantation (26.2% vs 14.6%; P < .001) and redo-SAVR (12.3% vs 6.9%; p < .001). TAVR explantation was independently associated with higher mortality (adjusted odds ratio [OR_adj], 1.3 [1.0-1.6]; P = .030). Severe mitral regurgitation (OR_adj, 1.2 [1.0-1.6]; P = .017), mitral stenosis (OR_adj, 2.0 [1.5-2.7; P < .001), and tricuspid regurgitation (OR_adj, 1.6 [1.3-1.9]; P < .001) were all associated with mortality, although these factors were not associated with disproportionately higher risk during TAVR explantation (P > .05).

Conclusions: TAVR explantation cases have a higher burden of severe concomitant valve disease than redo-SAVR cases. Heart teams should consider these findings when discussing initial procedure choices for patients with multivalve disease, given their extreme risk at time of TAVR explantation.

Background: Anastomotic leak after esophagectomy is a major cause of morbidity and mortality. We sought to identify the prevalence of anastomotic leak, stratified by operative approach and disease etiology, as well as risk factors for leak.

Methods: A retrospective cohort analysis using The Society of Thoracic Surgeons General Thoracic Surgery Database was conducted on patients who underwent esophagectomy with gastric reconstruction between 2009 and 2021. Baseline characteristics and postoperative outcomes were compared between patients who did and did not develop an anastomotic leak. Multivariable mixed effects logistic regression models identified risk factors for leak.

Results: Of 18,419 patients, 3416 (19%) developed an anastomotic leak. Patients who leaked had more comorbidities, including obesity and diabetes. There was no difference in leak based on disease etiology (P = .435.) Patients with anastomotic leak had increased 30-day mortality (7% vs 4%, P < .001), reoperation (58% vs 10%, P < .001), and longer lengths of stay (18 vs 10 days, P < .001). On multivariable analysis, obesity (odds ratio [OR], 1.27; 95% CI, 1.16-1.38; P < .001), diabetes (OR, 1.14; 95% CI, 1.04-1.25; P = .006), and smoking (OR, 1.26; 95% CI, 1.15-1.37; P < .001) were independently predictive of anastomotic leak. Compared with an open 2-field, a transhiatal (OR, 1.35; 95% CI, 1.17-1.55; P < .001) or 3-field esophagectomy (OR, 1.46; 95% CI, 1.25-1.70; P < .001) was more likely to leak. A robotic approach was associated with an increased risk of leak (OR, 1.28; 95% CI, 1.03-1.08; P < .001), however lost significance in a modern subgroup from 2018-2021.

Conclusions: Obesity, diabetes, smoking, pulmonary hypertension, and a cervical anastomosis are risk factors for anastomotic leak regardless of disease etiology. These important clinical risk factors identify an opportunity for modifiable risk reduction with aggressive medical optimization perioperatively.

Background: This study describes in detail the clinical burden of malperfusion associated with acute type A aortic dissection (ATAAD) in a large, national cohort and the effect of treatment strategy on outcomes.

Methods: All patients undergoing repair of ATAAD between 2017 and 2020 in The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database were studied. Malperfusion was defined using STS definitions on the basis of imaging or the surgeon's evaluation. Multivariable logistic regression was used to analyze the effect of patient and treatment factors on outcomes in patients with and without malperfusion.

Results: A total of 9958 patients undergoing ATAAD repair were studied. Preoperative malperfusion occurred in 27.7% (2748 of 9958) of cases and most often involved the extremity (14.9%; 1484 of 9958), renal (10.2%), or cerebral (9.8%) vascular beds. Operative mortality was much greater among patients with malperfusion (26.8% vs 13.6%; P < .001). After adjustment, coronary malperfusion was associated with the highest odds of mortality (odds ratio, 2.28; 95% CI, 1.85-2.81; P < .001) followed by mesenteric malperfusion (odds ratio, 1.82; 95% CI, 1.45-2.28; P < .001). Cerebral malperfusion was not independently associated with significantly increased odds of mortality (odds ratio, 1.14; 95% CI, 0.94-1.38; P = .18). Partial arch replacement (zone 1 or zone 2) compared with ascending aorta or hemiarch replacement only showed a similar rate of mortality in patients with malperfusion (24.8% vs 26.9%; P = .99) and without malperfusion (11.6% vs 13.6%; P = .54).

Conclusions: Preoperative malperfusion in ATAAD was common and associated with significant operative mortality, which varied according to the malperfused region. Partial aortic arch replacement, compared with ascending aorta or hemiarch replacement alone, was not associated with increased mortality.

Background: Socioeconomic disadvantage and Medicaid insurance have been linked with inferior survival following heart transplantation, yet the contributing mechanisms remain to be elucidated. We evaluated the association of Medicaid with the development of cardiac allograft vasculopathy(CAV).

Methods: We considered heart transplant recipients ≥18years within the 2004-2022 Organ Procurement and Transplantation Network. CAV was defined as any evidence of angiographic coronary disease. Institutional volume was computed, with hospitals in the highest quartile (≥19cases/year) categorized as High-Volume Centers. Patients were stratified by insurance into the Medicaid and Non-Medicaid cohorts. The study period was divided into the pre-Affordable Care Act (ACA; 2004-2013) and post-ACA eras (2014-2022).

Results: Of 37,073 heart transplant recipients, 4,875(13%) were insured by Medicaid. The overall incidence of CAV was 31%. Following risk-adjustment, Medicaid insurance was linked with significantly greater likelihood of developing CAV over 5 years (Hazard Ratio[HR] 1.08, 95%Confidence Interval[CI] 1.01-1.16). Importantly, this effect seems to have emerged in the post-ACA era (Pre-ACA HR 1.07, CI 0.84-1.36; Post-ACA HR 1.11, CI 1.02-1.21). Furthermore, among patients at High-Volume Centers, Medicaid insurance was linked with similar CAV likelihood (HR 1.04, CI 0.95-1.14). Yet, considering those treated at non-High-Volume Centers, Medicaid was associated with significantly greater CAV hazard (HR 1.14, CI 1.03-1.26). Overall, Medicaid remained associated with inferior patient (HR 1.31, CI 1.21-1.42) and allograft survival at 5-years (HR 1.29, CI 1.19-1.39).

Conclusions: Medicaid-insured recipients faced inferior survival and greater risk of CAV over 5-years. Our work encourages closer follow-up and treatment for vulnerable populations in the months and years post-transplantation.

Background: To evaluate the proportion of lung cancer patients who would have qualified for lung cancer screening under different eligibility criteria in the Boston Lung Cancer Study (BLCS).

Methods: BLCS participants diagnosed with lung cancer from 1992-2024 were identified for analysis. The proportion of patients who would have qualified for screening under the 2021 U.S. Preventive Services Task Force (USPSTF) (age 50-80, >20-pack-years, <15 quit-years), 20-year duration (age 50-80, 20-year smoking duration, <15 quit-years), American Cancer Society (age 50-80, >20-pack-years), NCCN-category-A (age >50, >20-pack-years), and NCCN-category-AB (aged >50, >20 pack-years OR >20-year smoking duration) guidelines were evaluated. We also evaluated the proportion of patients with a smoking history ineligible for screening under the aforementioned guidelines who had a PLCOm2012 risk score > 1.0%.

Results: Of 7,186 patients meeting inclusion criteria, 33.4% currently smoked, 52.1% formerly smoked, and 14.5% had never smoked. Among these patients, 46.1% met the USPSTF guideline, 48.9% met the 20-year duration guideline, 61.0% met the American Cancer Society guideline, 66.1% met the NCCN-category-A guideline, and 71.7% met the NCCN-category-AB guideline. While the PLCOm2012 1.0% risk threshold identified 52.2% of patients with a smoking history who were ineligible for screening under the USPSTF criteria, the PLCOm2012 1.0% risk threshold excluded the majority of patients with <20 pack-years.

Conclusions: In this analysis of 7,186 lung cancer patients, only 46.1% would have met the USPSTF criteria. Including a smoking duration criterion and removing the 15-years-since-quitting criterion from the USPSTF guideline would increase the proportion of patients eligible for screening.

Background: Prospective randomized trials have demonstrated noninferior survival between sublobar resection and lobectomy in healthy non-small cell lung cancer (NSCLC) patients with tumors ≤2cm. However, some patient attributes are not well represented in randomized trials and uncertainty remains in the widespread applicability of randomized trial nodal dissection protocols.

Methods: Patients with ≤2cm, node-negative NSCLC (cT1N0) in the Society of Thoracic Surgeons prospective database were linked to Medicare survival data using a probabilistic matching algorithm. Survival was assessed by propensity score weighted Kaplan Meier analysis.

Results: Overall, 20,031 patients were identified including 11,976 lobectomy, 2,586 segmentectomy, and 5,469 wedge resection patients. Fewer lymph nodes were sampled in sublobar patients (mean 5.5 vs 12.8) and pathologic upstaging was less common (7.1% vs 14.2%). Overall survival following sublobar and lobar resection was similar within groups under-studied in recent trials including age ≥75 years (p=0.07), FEV1=10-59% (p=0.14), and Zubrod performance status 2-3 (p=0.23). When sublobar resection was performed with inadequate nodal evaluation (<2 nodes removed), the survival was inferior to lobectomy (p<0.001). Among patients with nodal upstaging, lobectomy was not associated with improved survival over sublobar resection (p=0.42).

Conclusions: The clinical trial finding that sublobar resections achieve similar survival to lobectomy in early-stage lung cancer appears to apply to older, less healthy patients in a real-world setting, provided adequate lymph node resection is performed. Performing a lobectomy in the setting of nodal upstaging, does not obviously improve survival. Further study is warranted to clarify the role of sublobar resection in the general population.

Background: The effect of anticoagulation on early postoperative outcomes after pulmonary valve replacement (PVR) with bioprosthetic valves and homografts is not yet defined. We hypothesized that short-term anticoagulation would be associated with improved valve durability.

Methods: Patients undergoing PVR or right ventricle-to-pulmonary artery conduits with a bioprosthetic or homograft valve >15 mm in diameter between January 2015 and April 2021 at Boston Children's Hospital were retrospectively compared by anticoagulation status. Survival, postoperative echocardiographic data, and the incidence of pulmonary valve reintervention and prosthetic valve dysfunction were compared using multivariable Cox and logistic regression analyses adjusted for a propensity score based on anticoagulation therapy.

Results: Among 531 patients with a median follow-up of 1.16 years, 130 received anticoagulation therapy. Freedom from reintervention was 99%, 92%, and 86% at 1, 3, and 5 years, respectively. Adjusted for propensity score, there was no association between reintervention and anticoagulation (hazard ratio, 0.78; 95% CI, 0.18-3.47; P = .75). The propensity score-adjusted rates of valve dysfunction were 9% in anticoagulated patients and 15% in non-anticoagulated patients (odds ratio, 0.54; 95% CI, 0.18-1.56; P = .25). There was no difference in early major bleeding rates between groups (3.4% vs 2.4%, P = .59) or in other postoperative outcomes. Only 1 of 18 (6%) of all bleeding events in the anticoagulated group occurred after starting anticoagulation.

Conclusions: Anticoagulation therapy appeared safe with no association with major postoperative bleeding. However, additional follow-up is necessary to assess its impact on midterm to long-term valve durability after PVR.

Background: Management guidelines for stable 3-vessel coronary artery disease have become a subject of debate. We aim to provide a benchmark for the survival of patients with normal ejection fraction, stable 3-vessel disease, and elective coronary artery bypass graft (CABG) surgery.

Methods: Data from consecutive patients with normal ejection fraction undergoing elective primary isolated CABG for 3-vessel disease in a diverse 11-center surgical network between 2008 and 2020 were analyzed. Survival data were obtained from the Centers for Disease Control and Prevention National Death Index and compared with an age- and sex-matched United States population. Mixed-effects modeling with "hospital" as a random effect was used to evaluate factors associated with all-cause mortality.

Results: Of 4061 patients included in this analysis, 893 (22%) were women, and the median age was 68 years (interquartile range, 61-74 years). Patients with elective CABG surgery for 3-vessel disease and normal ejection fraction demonstrated improved survival compared with an age- and sex-matched United States population, with significantly increasing relative survival over time. Factors associated with mortality included age ≥65 years (hazard ratio [HR], 1.71; P < .001), male sex (HR, 1.32; P = .028), diabetes (HR, 1.4; P = .002), dialysis (HR, 2.41; P = .03), moderate or severe chronic lung disease (HR, 1.68; P < .001), and peripheral arterial disease (HR, 2.05; P < .001).

Conclusions: Patients with stable 3-vessel disease and normal ejection fraction who underwent elective CABG demonstrated improved survival compared with an age- and sex-matched United States population. With this benchmark, further research can better elucidate the relative role of surgery and medical therapy in this patient population.

Background: Valve-sparing root replacement (VSRR) with the David technique is an established therapy for aortic root pathology in young patients. This study evaluated short- and long-term outcomes between VSRR and aortic root replacement (ARR) with a biological-valved conduit in sexagenarians.

Methods: A multicenter retrospective review from 2002 to 2022 identified 299 sexagenarians undergoing aortic root surgery, among whom 82 (27.4%) underwent VSRR and 217 (72.6%) underwent bio-Bentall. Inverse probability of treatment weighting (IPTW) was applied to balance clinical variables. Median follow-up was 15 years (interquartile range, 12-18 years). Study end points were in-hospital mortality, long-term survival, freedom from reintervention, and recurrence of at least moderate aortic regurgitation (AR).

Results: There were no major differences in baseline characteristics. The incidence of bicuspid valves (VSRR, 4.9%; ARR, 19%), severe AR (42% vs 51%), type A aortic dissection (1.2% vs 6.9%), and reoperation (4% vs 23%) were higher in ARR. After IPTW, there was no difference in in-hospital mortality (VSRR, 1.2%; ARR, 4.6%; P = .3). The incidence of neurologic complications (P = .003) and permanent pacemaker implantation (P = .022) were significantly higher in the bio-Bentall group. After IPTW, 10-year survival did not differ between VSRR (87%) and ARR (80%; P = .176). However, cardiac survival was significantly higher in VSRR patients (98% vs 92%, P = .018), with deaths mainly due to infective endocarditis and end-stage heart failure. No difference was reported in reoperation/recurrence of at least moderate AR among the groups at 10 years, with only 1 patient undergoing reintervention after bio-Bentall (P = .117).

Conclusions: David and bio-Bentall procedures have low in-hospital mortality and good long-term survival in sexagenarians. VSRR is associated with improved long-term cardiac survival, lower rates of infective endocarditis, permanent pacemaker implantation, and heart failure episodes, with similar rates of reintervention/recurrence of moderate AR.